AbbVie Inc. $ABBV Stock Position Boosted by Royal Fund Management LLC

Key Points

• Royal Fund Management increased its AbbVie position by 10.2% in the third quarter to 56,001 shares valued at approximately $14.65 million. Institutional investors collectively own 70.23% of the company.
• Analysts maintain a broadly positive outlook, with AbbVie receiving a “Moderate Buy” consensus rating and an average price target of $279.86; several firms recently raised their targets, including Morgan Stanley to $310.
• AbbVie’s growth outlook is supported by SKYRIZI and RINVOQ, while the company continues to offer a $1.73 quarterly dividend yielding about 2.4%. However, investors face near-term earnings uncertainty given the stock’s premium valuation and proximity to its 52-week high.

Royal Fund Management LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 10.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,001 shares of the company's stock after buying an additional 5,173 shares during the period. AbbVie comprises approximately 1.1% of Royal Fund Management LLC's holdings, making the stock its 18th biggest holding. Royal Fund Management LLC's holdings in AbbVie were worth $14,649,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. Burk Holdings LLC bought a new stake in AbbVie during the second quarter valued at $30,000. Merkkuri Wealth Advisors LLC bought a new position in shares of AbbVie during the first quarter valued at approximately $34,000. Marquette Asset Management LLC grew its stake in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock worth $35,000 after buying an additional 48 shares during the last quarter. IMG Wealth Management Inc. boosted its holdings in shares of AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after acquiring an additional 153 shares during the period. Finally, Principia Wealth Advisory LLC increased its holdings in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock worth $40,000 after acquiring an additional 44 shares during the period. Institutional investors and hedge funds own 70.23% of the company's stock.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ABBV shares. Oppenheimer raised their price target on AbbVie from $244.00 to $258.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. Argus lifted their price target on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Leerink Partners boosted their target price on shares of AbbVie from $245.00 to $279.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Bank of America reaffirmed a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Morgan Stanley upped their price objective on shares of AbbVie from $296.00 to $310.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $279.86.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

AbbVie Price Performance

Shares of AbbVie stock traded up $0.47 during midday trading on Friday, hitting $285.66. The company had a trading volume of 4,625,678 shares, compared to its average volume of 5,199,403. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. The business's 50 day simple moving average is $266.33 and its two-hundred day simple moving average is $241.77. The stock has a market cap of $504.70 billion, a PE ratio of 80.69, a P/E/G ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter last year, the company earned $2.97 earnings per share. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's dividend payout ratio is presently 195.48%.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.